Hemoglobinopathy: Difference between revisions
Line 33: | Line 33: | ||
{{familytree | | | | | | | |!| | | | | | | |)| E11 | | | | | | | | | | | | | | | | | | | | | | |E11=S with other [[Hemoglobin|Hb]] variants: D, O-Arab, other | | |}} | {{familytree | | | | | | | |!| | | | | | | |)| E11 | | | | | | | | | | | | | | | | | | | | | | |E11=S with other [[Hemoglobin|Hb]] variants: D, O-Arab, other | | |}} | ||
{{familytree | | | | | | | |!| | | | | | | |!| | | | | | | | | | | | | | | | | | | | | | | | | | }} | {{familytree | | | | | | | |!| | | | | | | |!| | | | | | | | | | | | | | | | | | | | | | | | | | }} | ||
{{familytree | | | | | | | |!| | | | | | | |`| E12 | | | | | | | | | | | | | | | | | | | | | | |E12=SF, [[Hemoglobin|Hb]] S/[[ | {{familytree | | | | | | | |!| | | | | | | |`| E12 | | | | | | | | | | | | | | | | | | | | | | |E12=SF, [[Hemoglobin|Hb]] S/[[Hereditary persistence of fetal hemoglobin|HPFH]] | | |}} | ||
Hereditary persistence of fetal hemoglobin|HPFH]] | | |}} | |||
{{familytree | | | | | | | |!| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | }} | {{familytree | | | | | | | |!| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | }} | ||
{{familytree | | |,|-|-|-|-|^|-|-|-|-|-|-|-|-|-|-|-|-|-|v|-|-|-|-|-|-|-|-|-|-|-|-|-|-|-|-|-|-|-|-|-|-|-|.|}} | {{familytree | | |,|-|-|-|-|^|-|-|-|-|-|-|-|-|-|-|-|-|-|v|-|-|-|-|-|-|-|-|-|-|-|-|-|-|-|-|-|-|-|-|-|-|-|.|}} |
Revision as of 18:55, 10 September 2018
Hemoglobinopathy Main page |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sogand Goudarzi, MD [2]
Overview
Hemoglobinopathy is a kind of genetic defect that results in abnormal structure of one of the globin chains of the hemoglobin molecule. Most common hemoglobinopathies include sickle-cell disease.The renge of clinical manifestations of the hemoglobinopathies are from mild hypochromic anemia to moderate hematological disease to severe.
Classification
Hemoglobinopathy be classified according to genetic and structure of hemoglobin into two main groups:[1]
Hemoglobinopathy classification | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantititive disorders of globulin chain synthesis | Qualitative disorders of globulin structure | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
α-thalassemia | β-thalassemia | De novo and acquired α-thalassemia | Sickle cell disorders | Hemoglobins with decreased stability (unstable hemoglobin variants) | Hemoglobins with altered oxygen affinity | Methemoglobin | Posttranslational modifications | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Deletion of α globin • one gene: α+ athalassemia • two gene in cis: α0 thalassemia • two gene in trans: homozygous α+ thalassemia (phenotype α0 thalassemia) • Three gene: HbH disease • Four genes: Hydrops fetalis with Hb Bart's | α-Thalassemia with mental retardation syndrome (ATR): • Due to large deletions on chromosome 16 involving the α-globin genes • Due to mutations of the ATRX transcription factor gene on chromosome X • α-Thalassemia associated with myelodysplastic | SA, sickle cell trait | Mutants causing congenital Heinz body hemolytic anemia | High/increased oxygen affinity stateso • Fetal red cells • Decreased RBC 2,3 BPG • Carboxyhemoglobinemia, HbCO • Structural variants | Congenital methemoglobinemia • Structural variants • Cytochrome b5 reductase deficiency | Nonenzymatic glycosylation | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Low/decreased oxygen affinity states • 2,3 BPG • Structural variants | Acquired (toxic) methemoglobinemia | Amino-terminal [[Acetylation |acetylation]] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Nondeletion mutants • Hb Constnt Spring • Other | α-Thalassemia associated with myelodysplastic syndromes (ATMDS) • Due to mutations of the ATRX gene | SS, sickle cell anemia/disease | Acquired instability—oxidant hemolysis • Drug-induced • G6PD deficiency | Amino-terminal carbamylation | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SC, HbSC disease | Deamidation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S/β thal, sickle β-thalassemia disease | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S with other Hb variants: D, O-Arab, other | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SF, Hb S/HPFH | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Clinical classification | Biochemical/genetic classification | Structural variants with β-thalassemia phenotype | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Minor/trait | Intermediate | Major | β0 thalassemia | β0 thalassemia | δ thalassemia | γ thalassemia | Lepore fusion gene | HbS/β-thalassemia | HbE/β-thalassemia | Other | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
δβ-thalassemia | εγδβ-thalassemia | HPFH | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
The range of clinical manifestations of the hemoglobinopathies are from mild hypochromic anemia to moderate hematological disease to severe.
Epidemiology and Demographics
Prevalence
- In 2008, the prevalence of hemoglobinopathy was estimated to be 7% of the worldwide population being carrier.[2]
- The most prevalance of hemoglobinopathy gene carriers in the world's are in South-East Asia(up to 70%) and Arab nations(up to 60).[2]
- In Russia is seen rare[2]
- Recent years it is increased in Germany.[3]
Race
α-thalassemias
It occure cur mainly in Africa, Arab nations, and, more frequently and South-East Asia.[4]
β-thalassemias
It occure cur mainly in Mediterranean countries, South-East Europe, Arab nations and Asia.[5]
Diagnosis
Hemoglobin testing(hemoglobin electrophoresi or chromatography) , red blood cell count, hemoglobin pattern, cardinal symptoms[6]
History & clinical symptoms | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Blood test | hemolysate | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Diagnosis of abnormal hemoglobins | Diagnisis of β-thalassemia | Dignisis of α-thalassemia | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Alkaline electrophoresis • acid electrophoresis •HPLC | Electrophoresis HPLC • HbA2,Hbf | Electrophoresis HPLC • DNA testing | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Evidence of abnormality,comparison of mobility with that of known abnormalities, if HBS suspected: solubility test | Separation/quantification | Evalution of all data and findings | Evalution of all data and findings | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Diagnisis of β-thalassemia | Dignisis of α-thalassemia | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
DNA sequencing if needed | DNA sequencing if needed(thalassemia major, thalassemia intermedia | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Evaluation of all data and findings(including blood count ethnic and origin | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Diagnosis of hemoglobinopathy | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
References
- ↑ Forget BG, Bunn HF (February 2013). "Classification of the disorders of hemoglobin". Cold Spring Harb Perspect Med. 3 (2): a011684. doi:10.1101/cshperspect.a011684. PMC 3552344. PMID 23378597.
- ↑ 2.0 2.1 2.2 Kohne E (August 2011). "Hemoglobinopathies: clinical manifestations, diagnosis, and treatment". Dtsch Arztebl Int. 108 (31–32): 532–40. doi:10.3238/arztebl.2011.0532. PMC 3163784. PMID 21886666.
- ↑ Cario H, Stahnke K, Sander S, Kohne E (January 2000). "Epidemiological situation and treatment of patients with thalassemia major in Germany: results of the German multicenter beta-thalassemia study". Ann. Hematol. 79 (1): 7–12. PMID 10663615.
- ↑ Kohne E (August 2011). "Hemoglobinopathies: clinical manifestations, diagnosis, and treatment". Dtsch Arztebl Int. 108 (31–32): 532–40. doi:10.3238/arztebl.2011.0532. PMC 3163784. PMID 21886666.
- ↑ Kohne E (August 2011). "Hemoglobinopathies: clinical manifestations, diagnosis, and treatment". Dtsch Arztebl Int. 108 (31–32): 532–40. doi:10.3238/arztebl.2011.0532. PMC 3163784. PMID 21886666.
- ↑ Herklotz R, Risch L, Huber AR (January 2006). "[Hemoglobinopathies--clinical symptoms and diagnosis of thalassemia and abnormal hemoglobins]". Ther Umsch (in German). 63 (1): 35–46. doi:10.1024/0040-5930.63.1.35. PMID 16450733.